{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:08:57Z","timestamp":1783930137775,"version":"3.55.0"},"reference-count":104,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI)-based combinations have become central systemic treatment options for advanced hepatocellular carcinoma (HCC) and are now being integrated into selected intermediate-stage settings. As tumor responses have improved, some patients who were not initially candidates for curative-intent treatment may later become candidates for resection, ablation, or liver transplantation. However, radiographic response alone does not define curative-intent candidacy, and no shared framework currently guides how post-immunotherapy response should be translated into a treatment decision. Terminology also differs regionally: Asian literature frames a resection-anchored paradigm, whereas Western practice uses transplant-anchored downstaging. This narrative review proposes a multidisciplinary framework for immunotherapy-based conversion to curative-intent treatment in HCC. We first clarify the lexicon of conversion, downstaging, bridging, neoadjuvant therapy, post-ICI transplantation, and drug-free or treatment-free status. We then summarize conversion-relevant evidence across key clinical decision settings, including transarterial chemoembolization (TACE)-unsuitable intermediate-stage disease, portal vein tumor thrombus or macrovascular invasion, borderline-resectable or locally advanced disease, and transplant downstaging or bridging. The central framework defines curative-intent transition through the intersection of three domains: technical suitability, oncologic suitability, and physiologic or liver-reserve suitability. Biomarkers, imaging response, tumor-marker kinetics, liver function, and treatment-related toxicity are discussed as inputs into candidacy rather than as response measures alone. Finally, we propose a multidisciplinary workflow and highlight lessons from pancreatic cancer, biliary tract cancer, and colorectal liver metastases. As an expert-opinion-based framework, this approach should structure multidisciplinary discussion rather than serve as validated selection criteria; harmonized terminology, prospective conversion registries, and conversion-specific endpoints are needed for prospective validation.<\/jats:p>","DOI":"10.3390\/cancers18142234","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:28:27Z","timestamp":1783927707000},"page":"2234","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy-Based Conversion to Curative-Intent Treatment in Hepatocellular Carcinoma: A Multidisciplinary Framework"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2899-4030","authenticated-orcid":false,"given":"Kizuki","family":"Yuza","sequence":"first","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA"},{"name":"Department of Gastroenterological Surgery, Yokohama City University, Yokohama 236-0004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global Trends in Hepatocellular Carcinoma Epidemiology: Implications for Screening, Prevention and Therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Facciorusso, A., Abd El Aziz, M.A., and Sacco, R. (2019). Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Cancers, 12.","DOI":"10.3390\/cancers12010036"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Abd El Aziz, M.A., Facciorusso, A., Nayfeh, T., Saadi, S., Elnaggar, M., Cotsoglou, C., and Sacco, R. (2020). Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines, 8.","DOI":"10.3390\/vaccines8040616"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"N. Engl. J. Med. Evid."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (CheckMate 9DW): An Open-Label, Randomised, Phase 3 Trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus Rivoceranib versus Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (CARES-310): Final Analysis of a Randomised, Open-Label, International, Phase 3 Study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus Pembrolizumab versus Lenvatinib plus Placebo for Advanced Hepatocellular Carcinoma (LEAP-002): A Randomised, Double-Blind, Phase 3 Trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus Atezolizumab versus Sorafenib for Advanced Hepatocellular Carcinoma (COSMIC-312): Final Results of a Randomised Phase 3 Study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without Bevacizumab with Transarterial Chemoembolisation in Hepatocellular Carcinoma (EMERALD-1): A Multiregional, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial Chemoembolisation Combined with Lenvatinib plus Pembrolizumab versus Dual Placebo for Unresectable, Non-Metastatic Hepatocellular Carcinoma (LEAP-012): A Multicentre, Randomised, Double-Blind, Phase 3 Study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for Hepatocellular Carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_17","first-page":"223","article-title":"Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update","volume":"14","author":"Bi","year":"2025","journal-title":"Liver Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.5582\/bst.2024.01394","article-title":"Chinese Expert Consensus on Sequential Surgery Following Conversion Therapy Based on Combination of Immune Checkpoint Inhibitors and Antiangiogenic Targeted Drugs for Advanced Hepatocellular Carcinoma (2024 Edition)","volume":"18","author":"Tang","year":"2025","journal-title":"Biosci. Trends"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","article-title":"Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"986\u2013994.e3; quiz e14\u201315","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver Transplantation for Hepatocellular Carcinoma: A Model Including \u03b1-Fetoprotein Improves the Performance of Milan Criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-Treat Outcomes of Patients with Hepatocellular Carcinoma Receiving Immunotherapy before Liver Transplant: The Multicenter VITALITY Study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative Nivolumab Monotherapy versus Nivolumab plus Ipilimumab in Resectable Hepatocellular Carcinoma: A Randomised, Open-Label, Phase 2 Trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant Cemiplimab for Resectable Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and Neoadjuvant Immunotherapies in Hepatocellular Carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","article-title":"Determining Safe Washout Period for Immune Checkpoint Inhibitors Prior to Liver Transplantation: An International Retrospective Cohort Study","volume":"82","author":"Moeckli","year":"2025","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/apt.70528","article-title":"Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma","volume":"63","author":"Aceituno","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000529574","article-title":"Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD Guidelines for the Treatment of Hepatocellular Carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival Benefit of Liver Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000507370","article-title":"A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","article-title":"APASL Clinical Practice Guidelines on Systemic Therapy for Hepatocellular Carcinoma-2024","volume":"18","author":"Lau","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/j.jhep.2026.01.012","article-title":"Conversion Surgery as a Missing Outcome in First-Line Immunotherapy Trials for Hepatocellular Carcinoma","volume":"84","author":"Xu","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101664","DOI":"10.1016\/j.jhepr.2025.101664","article-title":"Impact of LEAP-012 and EMERALD-1 in the Management of HCC","volume":"8","author":"Singal","year":"2026","journal-title":"JHEP Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus Lenvatinib and Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Phase II Study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.1097\/JS9.0000000000001819","article-title":"Lenvatinib plus Drug-Eluting Bead Transarterial Chemoembolization with\/without Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma Larger than 7 Cm with Major Portal Vein Tumor Thrombosis: A Multicenter Retrospective Cohort Study","volume":"110","author":"Cai","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology\/RTOG 1112 Phase 3 Randomized Clinical Trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101658","DOI":"10.1016\/j.jhepr.2025.101658","article-title":"Pembrolizumab and Stereotactic Body Radiotherapy Combined in Advanced Hepatocellular Carcinoma Post Sorafenib\u2014A Phase II Trial (PEMRAD)","volume":"8","author":"Mesci","year":"2026","journal-title":"JHEP Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000535514","article-title":"A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)","volume":"13","author":"Ichida","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41392-026-02708-2","article-title":"Sintilimab (PD-1 Inhibitor) plus Lenvatinib as Conversion Therapy Followed by Sequential Surgery (SILENSES) for Advanced Unresectable Hepatocellular Carcinoma: A Phase II, Expansion Trial","volume":"11","author":"Lu","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus Ipilimumab for Potentially Resectable Hepatocellular Carcinoma: Long-Term Efficacy and Biomarker Exploration","volume":"84","author":"Lin","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e003311","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-Arterial Chemoembolization as a Loco-Regional Inducer of Immunogenic Cell Death in Hepatocellular Carcinoma: Implications for Immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus Standard Dosimetry Approach of Selective Internal Radiation Therapy in Patients with Locally Advanced Hepatocellular Carcinoma (DOSISPHERE-01): A Randomised, Multicentre, Open-Label Phase 2 Trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological Response Following Neoadjuvant Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Cross-Trial, Patient-Level Analysis","volume":"25","author":"Stefanini","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus Bevacizumab versus Active Surveillance in Patients with Resected or Ablated High-Risk Hepatocellular Carcinoma (IMbrave050): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","article-title":"Updated Data from IMbrave050: Adjuvant Atezolizumab plus Bevacizumab for High-Risk Hepatocellular Carcinoma","volume":"84","author":"Yopp","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e233051","DOI":"10.1148\/radiol.233051","article-title":"The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors","volume":"312","author":"Wiggermann","year":"2024","journal-title":"Radiology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"833\u2013846; discussion 846\u2013848","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease","volume":"206","author":"Katz","year":"2008","journal-title":"J. Am. Coll. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.6004\/jnccn.2014.0106","article-title":"Pancreatic Adenocarcinoma, Version 2.2014: Featured Updates to the NCCN Guidelines","volume":"12","author":"Tempero","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1097\/AS9.0000000000000557","article-title":"International Validation and Refinement of Oncological Borderline Resectability Criteria for Hepatocellular Carcinoma Using Tumor Burden Score to Predict Survival","volume":"6","author":"Akabane","year":"2025","journal-title":"Ann. Surg. Open"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC Strategy for Prognosis Prediction and Treatment Recommendations: The 2026 Update","volume":"84","author":"Reig","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.surg.2023.08.024","article-title":"An Attempt to Establish and Apply Global Benchmarks for Liver Resection of Malignant Hepatic Tumors","volume":"174","author":"Alaimo","year":"2023","journal-title":"Surgery"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/bjs.11464","article-title":"Hepatocellular Carcinoma Tumour Burden Score to Stratify Prognosis after Resection","volume":"107","author":"Tsilimigras","year":"2020","journal-title":"Br. J. Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000004346","article-title":"Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria","volume":"272","author":"Tsilimigras","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of Liver Function in Patients with Hepatocellular Carcinoma: A New Evidence-Based Approach\u2014The ALBI Grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/bjs.10095","article-title":"Albumin-Bilirubin versus Child-Pugh Score as a Predictor of Outcome after Liver Resection for Hepatocellular Carcinoma","volume":"103","author":"Wang","year":"2016","journal-title":"Br. J. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100557","DOI":"10.1016\/j.jhepr.2022.100557","article-title":"The ALBI Score: From Liver Function in Patients with HCC to a General Measure of Liver Function","volume":"4","author":"Toyoda","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"109723","DOI":"10.1016\/j.ejso.2025.109723","article-title":"Dynamic ALBI Score and FIB-4 Index Trends to Predict Complications after Resection of Hepatocellular Carcinoma: A K-Means Clustering Approach","volume":"51","author":"Akabane","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/SLA.0000000000000743","article-title":"Sarcopenia Impacts on Short- and Long-Term Results of Hepatectomy for Hepatocellular Carcinoma","volume":"261","author":"Voron","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e203336","DOI":"10.1001\/jamasurg.2020.3336","article-title":"Association of Sarcopenia and Body Composition with Short-Term Outcomes After Liver Resection for Malignant Tumors","volume":"155","author":"Berardi","year":"2020","journal-title":"JAMA Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic Decompensation Is the Major Driver of Mortality in Patients with HCC Treated with Atezolizumab plus Bevacizumab: The Impact of Successful Antiviral Treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.cgh.2024.12.028","article-title":"Liver Decompensation in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Real-Life Study","volume":"23","author":"Stella","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.jhep.2025.07.020","article-title":"Establishing Hepatic Decompensation as a Meaningful Clinical Outcome during Systemic Therapy for Hepatocellular Carcinoma","volume":"83","author":"Cabibbo","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e6835","DOI":"10.1002\/cam4.6835","article-title":"PIVKA-II Combined with Tumor Burden Score to Predict Long-term Outcomes of AFP-negative Hepatocellular Carcinoma Patients after Liver Resection","volume":"13","author":"Qiu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00261-017-1281-6","article-title":"Locoregional Therapies for Hepatocellular Carcinoma and the New LI-RADS Treatment Response Algorithm","volume":"43","author":"Kielar","year":"2018","journal-title":"Abdom. Radiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"109683","DOI":"10.1016\/j.ejso.2025.109683","article-title":"Impact of Disparity between Imaging and Pathological Tumor Size on Cancer-Specific Prognosis among Patients with Hepatocellular Carcinoma","volume":"51","author":"Akabane","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-Specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1158\/1078-0432.CCR-17-0950","article-title":"Characterization of the Immune Microenvironment in Hepatocellular Carcinoma","volume":"23","author":"Yarchoan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and Non-Inflamed Classes of HCC: A Revised Immunogenomic Classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH Limits Anti-Tumour Surveillance in Immunotherapy-Treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000545494","article-title":"Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab","volume":"15","author":"Stefanini","year":"2025","journal-title":"Liver Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma","volume":"9","author":"Bresnahan","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-Tumoral Tertiary Lymphoid Structures Are Associated with a Low Risk of Early Recurrence of Hepatocellular Carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2400934","DOI":"10.1200\/PO-24-00934","article-title":"Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients with Hepatocellular Carcinoma","volume":"9","author":"Abdelrahim","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41416-025-03296-8","article-title":"Circulating Tumour DNA for a Minimal Residual Disease Assessment and Recurrence Risk in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"134","author":"Buonopane","year":"2026","journal-title":"Br. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41591-025-04177-6","article-title":"Humoral IgG1 Responses to Tumor Antigens Underpin Clinical Outcomes in Immune Checkpoint Blockade","volume":"32","author":"Sweeney","year":"2026","journal-title":"Nat. Med."},{"key":"ref_86","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma. J. Hepatol., 82, 315\u2013374."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1245\/s10434-013-3413-8","article-title":"Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic Is Associated with Improved Clinical Outcome","volume":"21","author":"Yopp","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s11605-011-1710-8","article-title":"Multidisciplinary Management of Recurrent Hepatocellular Carcinoma Following Liver Transplantation","volume":"16","author":"Kneuertz","year":"2012","journal-title":"J. Gastrointest. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Kinsey, E., and Lee, H.M. (2024). Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape. Cancers, 16.","DOI":"10.3390\/cancers16030666"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jhep.2024.05.041","article-title":"Integration of New Technologies in the Multidisciplinary Approach to Primary Liver Tumours: The next-Generation Tumour Board","volume":"81","author":"Nault","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised Management of Patients with Hepatocellular Carcinoma: A Multiparametric Therapeutic Hierarchy Concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jhep.2026.01.009","article-title":"Revisiting Prophylactic Corticosteroids to Mitigate Severe Immune-Related Adverse Events in Hepatocellular Carcinoma","volume":"84","author":"Shen","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ponziani, F.R., Giannelli, V., Marrone, G., Martini, S., Morelli, M.C., Pagano, D., Baroni, G.S., Germani, G., Burra, P., and Toniutto, P. (2026). Expert Consensus on the Use of Immune Checkpoint Inhibitors in the Liver Transplant Setting: Guidance from the Liver Transplant Committee of the Italian Association for the Study of the Liver (AISF). Am. J. Transplant., in press.","DOI":"10.1016\/j.ajt.2026.02.024"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Dalbeni, A., Auriemma, A., Vicardi, M., Cattazzo, F., Bellucco, M.E., Mazzarelli, C., Villa, F., Dispinzieri, G., Natola, L.A., and Sold\u00e0, C. (2026). Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study. Liver Cancer.","DOI":"10.1159\/000549738"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/apt.70090","article-title":"Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort","volume":"61","author":"Zarka","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_97","first-page":"EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"N. Engl. J. Med. Evid."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in Combination with Gemcitabine and Cisplatin Compared with Gemcitabine and Cisplatin Alone for Patients with Advanced Biliary Tract Cancer (KEYNOTE-966): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1245\/s10434-025-17776-x","article-title":"Oncological Resectability Criteria for Intrahepatic Cholangiocarcinoma: A Preoperative Framework for Multidisciplinary Management","volume":"32","author":"Kawashima","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yuza, K., Akabane, M., and Pawlik, T.M. (2026). Intrahepatic Cholangiocarcinoma: Contemporary Approaches to Surgical, Systemic, and Liver-Directed Therapy. Livers, 6.","DOI":"10.3390\/livers6020024"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"644\u2013657; discussion 657\u2013658","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-Term Survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","article-title":"Upfront FOLFOXIRI plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 plus Bevacizumab Followed by FOLFIRI plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Filoni, E., Musci, V., Di Rito, A., Inchingolo, R., Memeo, R., and Mannavola, F. (2023). Multimodal Management of Colorectal Liver Metastases: State of the Art. Oncol. Rev., 17.","DOI":"10.3389\/or.2023.11799"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Santiago, L., Huntley Pascual, D., S\u00e1nchez Lara, J.S., Huerta, M., and Dorcaratto, D. (2026). How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer. Cancers, 18.","DOI":"10.3390\/cancers18030489"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2234\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:31:31Z","timestamp":1783927891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":104,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142234"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142234","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}